Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 484

1.

A Review of the Clinical Subgroup Analyses From the RE-LY Trial.

Kumar R, Rahman AM, Henry BL.

Rev Cardiovasc Med. 2016;17(1-2):40-48.

PMID:
27667379
2.

Oral Anticoagulant Use in Atrial Fibrillation-Associated Ischemic Stroke: A Retrospective, Multicenter Survey in Northwestern China.

Zhang J, Yang XA, Zhang Y, Wei JY, Yang F, Gao H, Jiao WW, Sun XL, Gao Q, Jiang W.

J Stroke Cerebrovasc Dis. 2016 Sep 16. pii: S1052-3057(16)30324-X. doi: 10.1016/j.jstrokecerebrovasdis.2016.08.042. [Epub ahead of print]

PMID:
27645612
3.

Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.

Coleman CI, Antz M, Bowrin K, Evers T, Simard EP, Bonnemeier H, Cappato R.

Curr Med Res Opin. 2016 Sep 20:1-7. [Epub ahead of print]

PMID:
27633045
4.

Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation.

Sanmartín-Fernández M, Marzal-Martín D.

Clin Appl Thromb Hemost. 2016 Sep 13. pii: 1076029616668404. [Epub ahead of print]

PMID:
27624737
5.

Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.

Ezekowitz MD, Pollack CV, Sanders P, Halperin JL, Spahr J, Cater N, Petkun W, Breazna A, Kirchhof P, Oldgren J.

Am Heart J. 2016 Sep;179:59-68. doi: 10.1016/j.ahj.2016.06.008. Epub 2016 Jun 19.

6.

Practical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants.

Trikha R, Kowey PR.

Cardiology. 2016 Sep 6;136(2):115-124. [Epub ahead of print]

PMID:
27595409
7.

Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis.

Katsanos AH, Mavridis D, Parissis J, Deftereos S, Frogoudaki A, Vrettou AR, Ikonomidis I, Chondrogianni M, Safouris A, Filippatou A, Voumvourakis K, Triantafyllou N, Ellul J, Karapanayiotides T, Giannopoulos S, Alexandrov AW, Alexandrov AV, Tsivgoulis G.

Ther Adv Neurol Disord. 2016 Sep;9(5):359-68. doi: 10.1177/1756285616659411. Epub 2016 Jul 20.

8.

[Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation].

Helms TM, Silber S, Schäfer A, Masuhr F, Palm F, Darius H, Schrör K, Bänsch D, Bramlage P, Hankowitz J, Karle CA, Stargardt T, Weil J, Geller JC.

Herzschrittmacherther Elektrophysiol. 2016 Sep;27(3):295-306. doi: 10.1007/s00399-016-0447-1. German.

PMID:
27576696
9.

Safety of Direct Oral Anticoagulants: Insights from Postmarketing Studies.

Villines TC, Peacock WF.

Am J Med. 2016 Aug 25. pii: S0002-9343(16)30653-2. doi: 10.1016/j.amjmed.2016.06.004. [Epub ahead of print]

10.

Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses.

Kilickap M, Bosch J, Eikelboom JW, Hart RG.

Can J Cardiol. 2016 Sep;32(9):1108-16. doi: 10.1016/j.cjca.2016.06.003. Epub 2016 Jun 14. Review.

PMID:
27568871
11.

Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.

Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators.

Clin Cardiol. 2016 Aug 26. doi: 10.1002/clc.22572. [Epub ahead of print]

12.

Risk impact of edoxaban in the management of stroke and venous thromboembolism.

Hurst KV, O'Callaghan JM, Handa A.

Vasc Health Risk Manag. 2016 Aug 11;12:329-35. doi: 10.2147/VHRM.S94679. eCollection 2016. Review.

13.

[Catheter-based closure of the left atrial appendage : Stroke prevention in atrial fibrillation].

Skurk C, Leistner DM, Park JW, Landmesser U.

Internist (Berl). 2016 Sep;57(9):844-55. doi: 10.1007/s00108-016-0113-z. German.

PMID:
27534868
14.

Novel oral anticoagulant management issues for the stroke clinician.

Wassef A, Butcher K.

Int J Stroke. 2016 Oct;11(7):759-67. doi: 10.1177/1747493016660100. Epub 2016 Jul 27. Review.

PMID:
27465882
15.

Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.

Björck F, Renlund H, Lip GY, Wester P, Svensson PJ, Själander A.

JAMA Cardiol. 2016 May 1;1(2):172-80. doi: 10.1001/jamacardio.2016.0199.

PMID:
27437888
16.

Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Hu MM, Wang J, Chien KL, Su CL, Lin SY, Wu FL, Lin ZF.

J Formos Med Assoc. 2016 Jul 14. pii: S0929-6646(16)30116-4. doi: 10.1016/j.jfma.2016.05.007. [Epub ahead of print]

17.

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.

Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA.

J Am Heart Assoc. 2016 Jun 13;5(6). pii: e003725. doi: 10.1161/JAHA.116.003725.

18.

Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".

Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR.

Circulation. 2016 Jul 12;134(2):e7-8. doi: 10.1161/CIRCULATIONAHA.116.022737. No abstract available.

PMID:
27400902
19.

Letter by Imprialos et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".

Imprialos K, Boutari C, Stavropoulos K.

Circulation. 2016 Jul 12;134(2):e5-6. doi: 10.1161/CIRCULATIONAHA.116.022220. No abstract available.

PMID:
27400901
20.

Letter by Bouatou et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".

Bouatou Y, El Biali M, Samer CF.

Circulation. 2016 Jul 12;134(2):e3-4. doi: 10.1161/CIRCULATIONAHA.116.022034. No abstract available.

PMID:
27400900
Items per page

Supplemental Content

Loading ...
Write to the Help Desk